Sue Wallcraft is a member of the Audit and Risk Management Committee and the Remuneration Committee. Sue is an experienced general counsel and company secretary with over 25 years’ experience in the pharmaceutical industry and health charities. She is a qualified English solicitor and brings significant legal and governance knowledge to the board. Sue is currently General Counsel and Company Secretary for Vernalis (R&D) Limited, a non-executive director of Medicines Discovery Catapult.
Susan Wallcraft
Latest news
-
Tribune Therapeutics raises EUR 37 million for next-generation anti-fibrotic therapies
-
Hillstar Bio closes $67 million Series A financing round
-
LifeArc invests in Maxion Therapeutics Series A